Logo
About usInnovation CMChallengesEuropa2iEntrepreneurshipR&D&I SearchAgentsEventsReports
en
Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compoundsCM Patents

Índice de la ficha

Updated at
24/07/2026
Numero publicacion
EP.1414828.A1
Fecha publicacion
06/05/2004
Numero solicitud
EP20020753134

En detalle

Resumen

Derivatives of ecteinascidin 736 of general formula (I) wherein the groups R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>4 </SUB>and R<SUB>5 </SUB>are each independently selected from the group consisting of H, OH, OR', SH, SR', SOR', SO<SUB>2</SUB>R', C(-O)R', C(-O)OR', NO<SUB>2</SUB>, NH<SUB>2</SUB>, NHR', N(R')<SUB>2</SUB>, NHC(O)R', CN, halogen, -O, substituted or unsubstituted C<SUB>1</SUB>-C<SUB>25 </SUB>alkyl, substituted or unsubstituted C<SUB>2</SUB>-C<SUB>18 </SUB>alkenyl, substituted or unsubstituted C<SUB>2</SUB>-C<SUB>18 </SUB>alkynyl, substituted or unsubstituted arly, substituted or unsubstituted heterocyclic; wherein X is independently selected of OR', CN, (-O), or H; wherein each of the R' groups is independently selected from the group consisting of H, OH, NO<SUB>2</SUB>, NH<SUB>2</SUB>, SH, CN, halogen, -O, C(-O)H, C(-O)CH<SUB>3</SUB>, CO<SUB>2</SUB>H, substituted or unsubstituted C<SUB>1</SUB>-C<SUB>25 </SUB>alkyl, substituted or unsubstituted C<SUB>1</SUB>-C<SUB>18 </SUB>alkenyl, substituted or unsubstituted C<SUB>2</SUB>-C<SUB>18 </SUB>alkynyl, substituted or unsubstituted aryl; wherein m is 0, 1 or 2; and wherein n is 0, 1, 2, 3, or 4, and their use as antitumoral agent.

Reivindicaciones

1. A compound of formula: <img class="EMIRef" id="460046602-ib0037" /> <img class="EMIRef" id="460046602-ib0038" /> <img class="EMIRef" id="460046602-ib0039" /> <img class="EMIRef" id="460046602-ib0040" /> <img class="EMIRef" id="460046602-ib0041" /> <img class="EMIRef" id="460046602-ib0042" /> <img class="EMIRef" id="460046602-ib0043" /> <img class="EMIRef" id="460046602-ib0044" /> <img class="EMIRef" id="460046602-ib0045" /> <img class="EMIRef" id="460046602-ib0046" /> <img class="EMIRef" id="460046602-ib0047" /> <img class="EMIRef" id="460046602-ib0048" /> <img class="EMIRef" id="460046602-ib0049" /> <img class="EMIRef" id="460046602-ib0050" /> <img class="EMIRef" id="460046602-ib0051" /> <img class="EMIRef" id="460046602-ib0052" /> <img class="EMIRef" id="460046602-ib0053" /> <img class="EMIRef" id="460046602-ib0054" /> <img class="EMIRef" id="460046602-ib0055" /> <img class="EMIRef" id="460046602-ib0056" /> <img class="EMIRef" id="460046602-ib0057" /> <img class="EMIRef" id="460046602-ib0058" /> <img class="EMIRef" id="460046602-ib0059" /> or <img class="EMIRef" id="460046602-ib0060" /> 2. A compound according to claim 1 of formula (27): <img class="EMIRef" id="460046602-ib0061" /> 3. A compound according to claim 1 of formula (30): <img class="EMIRef" id="460046602-ib0062" /> 4. A compound according to claim 1 of formula (31): <img class="EMIRef" id="460046602-ib0063" /> 5. A compound according to claim 1 of formula (33): <img class="EMIRef" id="460046602-ib0064" /> 6. A compound according to claim 1 of formula: <img class="EMIRef" id="460046602-ib0065" /> 7. A compound according to claim 1 of formula (2): <img class="EMIRef" id="460046602-ib0066" /> 8. A compound according to claim 1 of formula (5): <img class="EMIRef" id="460046602-ib0067" /> 9. A compound according to claim 1 of formula (6): <img class="EMIRef" id="460046602-ib0068" /> 10. A compound according to claim 1 of formula (8): <img class="EMIRef" id="460046602-ib0069" /> 11. A pharmaceutical composition which contains a compound according to any preceding claim together with a pharmaceutically acceptable diluent. 12. The use of a compound according to any of claims 1 to 10 in the preparation of a medicament for treatment of cancer.

Etiquetas

Inventores
Martinez ValentinGallego PilarCuevas CarmenMunt SimonManzanares IgnacioSimon MuntValentin MartinezIgnacio ManzanaresCarmen CuevasPilar GallegoIgnacio Martinez Valentin CuevMartinez Valentin,Cuevas Carmen,Gallego Pilar,Munt Simon,Manzanares IgnacioMartinez, ValentinGallego, PilarCuevas, CarmenMunt, SimonManzanares, IgnacioMartines ValentinGal Ego PilarKuehvas KarmenMant SajmonMansanares IgnasioМАРТИНЕС Валентин(ES)ГАЛЬЕГО Пилар(ES)КУЭВАС Кармен(ES)МАНТ Саймон(ES)МАНСАНАРЕС Игнасио(ES)
Solicitantes
Pharma Mar SaPharma Mar SFarma Mar S AФарма Мар, СА (EsMartinez ValentinGallego PilarCuevas CarmenMunt SimonManzanares Ignacio
Clasificacion ipc
A61K 31/ 4995 A IA61P 35/ 00 A IC07D 515/ 22 A IA61K 31/ 438 A IA61K 31/ 4985 A IA01N 43/ 58 A IA01N 43/ 60 A IA61K 31/ 495 A IA61K 31/ 498 A IA61K 31/ 50 A IC07D 487/ 00 A IC07D 491/ 00 A IC07D 498/ 22 A IC07D 513/ 00 A I
Clasificacion cpc
4C086/AA024C086/AA034C086/CB314C086/MA024C086/MA054C086/NA144C086/ZB26A61K31/4995A61P35/00C07D515/224C086/AA014C086/BC944C086/MA014C086/MA04514/249540/468
Logo

Innovation CM
Challenges
Europa2i
Entrepreneurship
R&D&I Search
Agents
Events
Reports
About us
Contact
Give us your opinion
Cookies
Legal notice
Privacy

© Copyright Espacio Madrileño de Investigación e Innovación 2026